[Reuters] - U.S. health regulators on Wednesday approved Regeneron Pharmaceuticals Inc's big-selling eye drug Eylea to treat diabetic retinopathy, the most common diabetic eye disease and a leading cause of blindness in adults. The Food and Drug Administration decision marked the fourth approval for Eylea, an injectable medicine that had sales of $2.78 billion [...]

[PR Newswire] - TARRYTOWN, N.Y., Feb. 10, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2014 and provided an update on development ... Read more on this. Regeneron Pharmaceuticals, Inc. (REGN), with a current value of $40.27B, opened this morning at $402.65. [...]

[Reuters] - Regeneron Pharmaceuticals Inc cut the top end of its full-year sales forecast for its blockbuster eye drug and reported a lower-than-expected adjusted quarterly profit, citing higher costs. The company's ... Read more on this. Regeneron Pharmaceuticals, Inc. (REGN), currently valued at $37.81B, finished yesterday at $395.26. A [...]

[PR Newswire] - TARRYTOWN, N.Y. and PARIS, Oct. 20, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that the first patients have been dosed ... Read more on this. Regeneron Pharmaceuticals, Inc. (REGN), currently valued at $36.69B, opened at $367.79. [...]

[at Investor's Business Daily] - In the current volatile market, shares of companies that boast strong fundamentals, like Regeneron Pharmaceuticals (REGN) and Michael Kors (KORS), will likely hold up well and are the top prospects for ... Read more on this. Regeneron Pharmaceuticals, Inc. (REGN), currently valued at $34.56B, opened this morning at [...]

Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) recently announced that positive data from a phase IIa study evaluating dupilumab (REGN668/SAR231893) for moderate-to-severe allergic asthma was published in the New England Journal of Medicine.
The study (n = 104) evaluated the efficacy and safety of dupilumab in patients suffering from moderate-to-severe persistent asthma whose disease was [...]

We recently maintained our Neutral recommendation on biopharmaceutical company, Regeneron Pharmaceuticals (REGN). Our target price is $195.00 per share.
Why the Reiteration?
Regeneron reported higher-than-expected earnings in the fourth quarter of 2012, on the back of strong sales of its eye-drug Eylea. The drug has performed well since its US launch in late 2011 for treating patients [...]

In case you didn’t know, three weeks ago was the J.P. Morgan Healthcare Conference in San Francisco. It’s a big deal with a who’s who of bigwigs in the industry...
>> Regeneron (Nasdaq: REGN): Have You Missed the Boat?

Regeneron Pharmaceuticals Inc. (REGN) recently suffered a setback in its efforts to expand the label of its drug Arcalyst. The US Food and Drug Administration (FDA) declined to approve Arcalyst for preventing gout flares in patients initiating uric acid-lowering therapy on the basis of the submitted data.
The US regulatory body issued a complete response letter [...]

Regeneron Pharmaceuticals (NASDAQ: REGN) announced that it had received approval for Eylea, a treatment for wet macular degeneration. The disease can cause blindness in patients and occurs when fluid leaks from blood vessels and affects the position of the macula in the eye, which initially distorts vision. The drug hopes to compete with the generic Avastin, which has historically been used off label, but has shown to have serious side effects if not packaged properly.
Eylea faces tough...

The stock market has had three consecutive up days this week. Friday may possibly be a consolidation day. We’ll just have to see what occurs. For now, we’re going to continue to look at stocks that are looking very well.
Comtech ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of drugmaker Regeneron Pharmaceuticals (Nasdaq: REGN ) popped 10% in intraday trading Friday after The New York Times reported that Roche's age-related [...]

Germany’s Bayer (BAYRY) recently submitted an application to the Japanese Ministry of Health, Labor and Welfare (MHLW) seeking approval to market its eye treatment VEGF (vascular endothelial growth factor) trap-eye (proposed trade name: Eylea) in the country.
The clearance is being sought to market the drug for treating patients suffering from the neovascular form of age-related [...]

Recently, the Dermatologic and Ophthalmic Advisory Committee of the US Food and Drug Administration (FDA) issued a positive opinion and unanimously recommended the US approval of Regeneron Pharmaceuticals Inc.’s (REGN) eye treatment VEGF (vascular endothelial growth factor) trap-eye (proposed trade name: Eylea).
The panel recommended the clearance of the candidate in the US for treating patients [...]

Seth Klarman's Baupost Group, which has $24 billion in assets under management, is opening its first overseas office later this year to take advantage of a spate of distressed debt sales caused by Europe's sovereign debt crisis, according to Bloomberg News, citing sources familiar with the matter. The new office will be located in London.
Jim [...]

I just closed out $REGN for a painful hit. I used the William B7 signal for entry.
Interestingly enough I started out really slow too because I didn’t want to get to big. I had no idea it was going to rip up over $10 higher. Had I used the improved William B9 signal I [...]

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) witnessed the correction of 3.23% to close at $35.31 with overall traded volume of 1.03 million shares in the last trading day. Its outstanding shares stood at 82.29 million. Its total market capitalization arrived at $2.91 billion.
AVANIR Pharmaceuticals (NASDAQ:AVNR) dropped by 4.53% and closed at $3.79 whereas total traded volume [...]

Regeneron Pharmaceuticals Inc.'s (REGN) third quarter 2010 net loss of 41 cents per share was wider than the Zacks Consensus Estimate of a net loss of 34 cents. The company suffered a loss of 1 cent per share in the year-ago quarter. The wider loss was attributable to lower revenues and higher expenses incurred in [...]

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) are higher on the session by 3.27%, currently trading at $26.85. The stock has been moving largely higher over the past four months after bouncing off of the $22.00 level and rallying above the 50-day and 200-day moving averages.
Options traders are buying calls on the name today. A short while ago the December $30.00 call was purchased 1,000 times, on the offer, on open interest of 1,677 contracts.
Overall call volume is now...

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today the completion of its previously announced underwritten public offering of 5,500,000 shares of Common Stock, as well as 825,000 additional shares of its Common Stock pursuant to the full exercise of the over-allotment option granted to the underwriter.
The total proceeds of the offering (before estimated offering expenses) were approximately $175.1 million. Citi acted as the sole book-running manager for the offering. The...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has increased the size of its previously announced underwritten public offering of Common Stock from 4,500,000 shares to 5,500,000 shares and agreed to an indicative price of $28.00 per share for the offering. Citi is serving as sole book-running manager for the offering. The offering is expected to close on October 13, 2010, subject to customary closing conditions. In addition, Regeneron has granted Citi a 30-day option...

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it intends, subject to market conditions, to offer 4,500,000 shares of its common stock pursuant to an underwriting agreement with Citi acting as the sole bookrunner.
The Company expects to use the net proceeds from the sale of the shares for general corporate purposes. Closing of the offering is expected to occur on or about October 11, 2010, subject to customary closing conditions. In addition, the Company intends to...

PiperJaffray says it is a buyer of Regeneron Pharmaceuticals (NASDAQ: REGN) ahead of pivotal VEGF Trap-Eye data in Age-related Macular Degeneration (AMD) in December.
If approved, we believe VEGF Trap-Eye could be a game changer for Regeneron pushing the company to profitability in 2012. Regeneron retains U.S. rights where there are >200,000 new cases of AMD each year. PiperJaffray conservatively forecasts sales of $710 million by 2015 with only 25% penetration. If VEGF Trap-Eye proves...

Regeneron Pharmaceuticals Inc.’s (REGN) second-quarter 2010 net loss of $25.5 million, or 31 cents per share, was narrower than the Zacks Consensus Estimate of a net loss of 38 cents. The company suffered a loss of $14.9 million, or 19 cents per share in the year-ago quarter. The wider year-over-year loss in the reported quarter [...]

Regeneron Pharmaceuticals Inc.’s (REGN) first-quarter loss of $30.5 million, or 38 cents per share, was narrower than the Zacks Consensus Estimate of a loss of 49 cents. The company suffered a loss of $15.4 million, or 19 cents per share in the year-ago quarter. This was due to higher research and development expenses although revenues [...]

Regeneron Pharmaceuticals Inc.’s (REGN) first-quarter loss of $30.5 million, or 38 cents per share, was narrower than the Zacks Consensus Estimate of a loss of 49 cents. The company suffered a loss of $15.4 million, or 19 cents per share in the year-ago quarter. This was due to higher research and development expenses although revenues [...]

Regeneron Pharmaceuticals Inc. (REGN) announced recently that is investing $40 million, which will result in the creation of up to 100 jobs in East Greenbush facility in Rensselaer County, coupled with another 300 jobs at its Westchester County facility, both in New York. The new positions will be created primarily for research.
Regeneron increased its presence [...]

Sanofi-Aventis (SNY) recently extended and expanded its antibody collaboration with biopharmaceutical company, Regeneron Pharmaceuticals, Inc. (REGN). The companies had initially entered into a collaboration agreement in 2007, which was scheduled to expire in 2012.
Under the extended agreement, Sanofi will increase its annual funding commitment by $60 million to $160 million from 2010. Moreover, the agreement [...]

Last week, Regeneron Pharmaceuticals, Inc. (REGN) announced the completion of enrollment in two late stage studies of its VEGF (vascular endothelial growth factor) trap-eye treatment for age-related macular degeneration (wet AMD), a leading cause of blindness in adults. Each of the randomized, double-masked trials has enrolled more than the target of 1,200 patients.
The company is [...]

On Friday, Sanofi-Aventis (SNY) and collaboration partner, Regeneron Pharmaceuticals (REGN) suffered a pipeline setback with the companies halting development of their late-stage pipeline candidate, aflibercept, for the treatment of pancreatic cancer.
Aflibercept, an anti-angiogenesis agent being developed for a variety of tumor types, was in a phase III study, which was evaluating the efficacy of the [...]